ECM
LXEO icon

ExodusPoint Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

ExodusPoint Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Sell
27,880
-84,292
-75% -$456K ﹤0.01% 1452
2026
Q1 		$644K Buy
+112,172
New +$795K 0.01% 1122
2025
Q4 		– Sell
-27,380
Closed -$182K – 1834
2025
Q3 		$182K Buy
+27,380
New +$132K ﹤0.01% 1399
2024
Q1 		– Sell
-34,172
Closed -$459K – 1768
2023
Q4 		$459K Buy
+34,172
New +$424K ﹤0.01% 1054

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ExodusPoint Capital Management's LXEO Position: Q2 2026 in Review

ExodusPoint Capital Management reduced its Lexeo Therapeutics (LXEO) stake by 75% in Q2 2026, selling an estimated $456K and leaving 27,880 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1452.

ExodusPoint Capital Management first reported a position in LXEO in Q4 2023 and has held it in 4 quarters since. The position peaked at $644K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • ExodusPoint Capital Management held 27,880 shares of Lexeo Therapeutics worth $130K as of Q2 2026.
  • ExodusPoint Capital Management sold 84,292 Lexeo Therapeutics shares in Q2 2026, an estimated $456K.
  • Lexeo Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #1452 holding.
  • ExodusPoint Capital Management first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • ExodusPoint Capital Management's Lexeo Therapeutics position peaked at $644K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.